October 2018 - Volume 28 - Issue 5

  • F.J. Lejeune
    W.J. Storkus
  • 0960-8931
  • 1473-5636
  • 6 issues / year
  • 11 of 63 Dermatology
    56 of 133 Medicine, Research & Experimental
    115 of 222 Oncology
  • 3.135

Current Issue Highlights


Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma: systematic review and meta-analysis of randomized-controlled trials

Menshawy, Amr; Eltonob, Abdelrahman A.; Barkat, Sarah A.; More

Melanoma Research. 28(5):371-379, October 2018.


Basic science


Translational research


Clinical research


High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitors

Teterycz, Pawel; Jagodzinska-Mucha, Paulina; Cybulska-Stopa, Bozena; More

Melanoma Research. 28(5):435-441, October 2018.

Epidemiology of melanoma



Early onset of diffuse melanosis cutis under pembrolizumab therapy illustrates the limitations of anti-PD-1 checkpoint inhibitors

Thiem, Alexander; Schummer, Patrick; Ueberschaar, Simon; More

Melanoma Research. 28(5):465-468, October 2018.